Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02297 潤邁德 - B
Listing Date2022/07/08
Listing Price6.240
  • 1.140 +0.040 (+3.636%)    Sink Below Listing Price
  • 15-min delayed, last update: 24/03/2023 18:00
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    15 lot
  • One Lot Success Rate

Rainmed Medical Limited founded in 2014, it is a China-based medical device company, with focus on the design, development and commercialization of coronary angiography-derived fractional flow reserve system (caFFR System) and coronary angiography-derived index of microvascular resistance system (caIMR System).

Its Core Products, caFFR System and caIMR System, used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (“CAD”). They are designed to eliminate the usage of pressure wires, significantly reduce the risk of technical errors and operation time, and improve physiological assessment.

Its caFFR System has obtained both certificates of CE Mark in Europe and NMPA approval in China. Building on its caFFR System and caIMR System, it aims to launch vascular interventional surgical robot, to automate the whole process of percutaneous coronary intervention (“PCI”) by 2024.


The Group had 81 approved patents, including 79 approved in China, one approved in the U.S. and one approved in Japan; 145 pending patent applications, including 106 in China and 39 overseas; 36 active PCT patent applications; 269 registered trademarks; and10 registered software copyrights. It also held six material patents and four material patent applications in relation to its caFFR System and four material patents and three material patent applications in relation to caIMR System.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot1000
No. of Offer Shares23.35M shares
No. of International Offer Shares21.01M shares
No. of HK Offer Shares2.34M shares
Offer Price$4.28 - $6.24
Stock Code2297
Sponsor(s)Huatai Financial Holdings (Hong Kong) Limited
Underwriter(s)Huatai Financial Holdings (Hong Kong) Limited, Zhongtai International Securities Limited, BOCOM International Securities Limited, Eddid Securities and Futures Limited, Livermore Holdings Limited
Application PeriodJun 27 (Mon) - noon, Jun 30 (Thu)
Price Determination DateJun 30 (Thu)
Result Announcement DateOn or before Jul 07 (Thu)
Result Announcement DateOn or before Jul 07 (Thu)
Dealings in Shares commence onJul 08, 2022. (Fri)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$4.28 - $6.24
Capitalization5.00B - 7.28B
NAV / share ($)$0.65 - $0.68 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 5.26, the net proceeds raised would be HKD 57.60M, of which
80% : To fund the research and development as well as commercialization of Core Products caFFR System and caIMR System
16.5% : To fund the ongoing research and development, manufacturing and commercialization of other pipeline products
3.5% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.